Noxopharm Ltd has released a press release.
NOX CEO interview on Radiotherapy Clinical Programs
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- St Vincents Hospital study passes first milestone
- DARRT-1 Clinical Study commences
- NOX raises $10.8 M to advance clinical program
- Evidence of Abscopal Responses in Patients
- NOX Reports NOX66 Clinical Data
Later from Noxopharm
- NOX CEO interview on near complete NOX66 chemotherapy trial
- NOX to present at American Society of Clinical Oncology
- End-of-Study Clinical Data shows benefit of NOX66
- Pre-Clinical data confirms Radio-Enhancing potential
- Release of DARRT-1 Preliminary Safety Data
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm